Nektar reports: “Positive Data from Phase 2 Trial “

As I have said in my earlier posts. I really like this company for its pipeline. Within the next 2 years I expect them to have started multiple Phase 3 studies. This is just the beginning. Let’s hope their PR machine works (I’ll help them a bit) 🙂
Check out the old post here!

Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting

Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response

SAN FRANCISCO, May 31, 2014 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of Lawrence Recht, M.D., Professor of Neurology and Neurosurgery, with co-investigator Seema Nagpal, M.D., Clinical Assistant Professor of Neurology and Neurological Sciences, Stanford School of Medicine.

You can read the news item by clicking here.
Most recent quote: [stock-tools exchange=”NASDAQ” symbol=”NKTR” image_height=”90″ image_width=”150″]

the Wiseguy

Stock trader, Owner and Administrator of "the-wiseguy.com". . . "TA is like surfing. You don't have to know a lot about het physics of tides to catch a good wave. You just have to be able to sense when it's happening and have the drive to act at the right time"

Geef een reactie

Deze website gebruikt Akismet om spam te verminderen. Bekijk hoe je reactie-gegevens worden verwerkt.